Barclays raised the firm’s price target on Genmab (GMAB) to DKK 2,500 from DKK 2,000 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: Late-Stage Oncology Pipeline Catalysts Underpin Buy Rating and Upside Potential
- Genmab discontinuing acasunlimab a ‘good decision,’ says Guggenheim
- Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline
- Genmab to discontinue clinical development of acasunlimab
- Genmab to discontinue further development of acasunlimab